Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Seymour JF, et al. Among authors: launonen a. Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573503 Free PMC article.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Seymour JF, et al. Among authors: launonen a. Haematologica. 2020 May;105(5):1465. doi: 10.3324/haematol.2020.246991. Haematologica. 2020. PMID: 32358081 Free PMC article. No abstract available.
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ, Guzauskas GF, FeLizzi F, Launonen A, Dawson K, Veenstra DL, Masaquel A. Spencer SJ, et al. Among authors: launonen a. J Manag Care Spec Pharm. 2021 May;27(5):615-624. doi: 10.18553/jmcp.2021.20424. Epub 2021 Feb 15. J Manag Care Spec Pharm. 2021. PMID: 33586513 Free PMC article.
DISCLOSURES: This study was funded by Genentech, a member of the Roche Group. The study sponsor was involved in study design, data interpretation, and writing of the report. ...Hoffmann-La Roche at the time this study was conducted; Launonen is an employees of F. Ho …
DISCLOSURES: This study was funded by Genentech, a member of the Roche Group. The study sponsor was involved in study design, data in …
74 results